Should a patient with an elevated hemoglobin level of 18.1 g/dL be referred to hematology?

Referral Decision for Hemoglobin 18.1 g/dL

A hemoglobin of 18.1 g/dL warrants hematology referral only if the patient is female; for males, this level falls just below the diagnostic threshold for erythrocytosis (≥18.5 g/dL), but initial workup should still be initiated in primary care before considering referral.

Diagnostic Threshold Assessment

The critical first step is determining whether true erythrocytosis exists:

• Erythrocytosis is formally diagnosed when hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women 1
• A hemoglobin of 18.1 g/dL in a male patient sits just below the diagnostic threshold but is concerning enough to warrant investigation
• A hemoglobin of 18.1 g/dL in a female patient clearly exceeds the threshold and requires full evaluation 1
• Confirm the elevation on at least two separate blood draws to exclude transient hemoconcentration before proceeding with extensive workup 1

Initial Primary Care Workup Before Referral

Before sending to hematology, the following tests should be ordered:

Priority Molecular and Hormonal Testing

• JAK2 V617F mutation analysis: Present in approximately 95% of polycythemia vera cases 1
  • If negative, JAK2 exon 12 mutation testing should follow 1
  • In a real-world cohort of patients with elevated hemoglobin, JAK2 mutations were detected in 10.9% of cases 2
• Serum erythropoietin (EPO) level 1:
  • Low or suppressed EPO suggests primary (clonal) erythrocytosis such as polycythemia vera
  • Normal or elevated EPO points toward secondary causes

Secondary Cause Screening

• Oxygen saturation measurement: Arterial oxygen saturation <92% indicates chronic hypoxemia as a secondary driver 1
• Smoking history and obesity assessment: In young adults with erythrocytosis, 59% were smokers and 43% were obese 3
• Renal function and imaging: To detect EPO-producing renal tumors 1

When to Refer to Hematology

Immediate referral is indicated if:

• JAK2 mutation is positive (either V617F or exon 12) 1
• Serum EPO is low or suppressed, suggesting primary erythrocytosis 1
• No secondary cause is identified after initial workup
• The patient is female with confirmed hemoglobin ≥16.5 g/dL on repeat testing 1

Delayed or no referral may be appropriate if:

• A clear secondary cause is identified (sleep apnea, chronic hypoxia, smoking)
• The elevation is transient and not confirmed on repeat testing
• The patient is male with hemoglobin <18.5 g/dL and a clear secondary etiology

Critical Clinical Pitfalls

Coexistence of Conditions

• Sleep apnea does not rule out polycythemia vera; in one series, 18% of erythrocytosis cases were PV, while 29% of patients with sleep apnea had concurrent PV 1
• Do not assume a secondary cause excludes primary disease

Iron Deficiency Masking

• Iron deficiency can mask polycythemia vera by lowering hemoglobin below diagnostic thresholds 1
• Reassess after iron repletion if clinical suspicion remains high

Thrombotic Risk

• Arterial thrombotic events occur in approximately 16% of patients at the time of PV diagnosis 1
• Progression to acute leukemia is reported in approximately 6.8% of PV patients 1
• These risks underscore the importance of not dismissing borderline elevations

Additional Mutations

• In JAK2-positive patients, additional mutations (TET2, DNMT3A, ASXL1) were found in 34.5% of cases, with prognostic implications 2
• Even JAK2-negative patients with erythrocytosis may harbor other myeloid mutations 2

Practical Algorithm

1. Confirm elevation with repeat hemoglobin on separate occasion 1
2. Order JAK2 V617F and serum EPO simultaneously 1
3. Screen for secondary causes: oxygen saturation, smoking history, renal function 1
4. If JAK2 positive OR EPO low: Refer to hematology for bone marrow biopsy 1
5. If JAK2 negative AND EPO normal/high: Treat identified secondary causes; refer if no cause found or hemoglobin remains elevated despite treatment
6. If female with confirmed Hgb ≥16.5 g/dL: Refer regardless of initial test results 1